ALFA Finder| Management target | Revenue 30.0% FY27 |
|---|
| Revenue growth | 29% YoY growth driven by 47% rise in Ayurveda products. |
|---|---|
| Margins | EBITDA margins stable at 41%; PAT margin at 28%. |
| Demand visibility | Strong; patient footfalls up 10% QoQ despite reducing government business. |
| Management confidence | Aggressive and visionary; focused on building a long-term wellness ecosystem. |
Growth
Revenue grew 29% YoY to ₹224 Cr; Ayurveda product sales jumped 47% while government business was slashed.
Outlook
Targeting ₹3,000 Cr revenue and ₹1,000 Cr PAT within 3-5 years with 7,000-10,000 beds.
Risks
One-time warrants valuation and capital gains (₹7.5 Cr) inflated other income. High dependence on celebrity-led TV advertising.
Last quarter's promises, checked
Delivered
- Guided 2,800-3,000 beds in 3-4 months → delivered 3,000 beds (= BEAT)
- Guided FY26 Revenue ₹801 Cr → delivered ₹801 Cr (= BEAT)
- Guided 50-50 Product/Service mix → delivered 52% products/48% services (= BEAT)
Partly delivered
- Guided 4x-5x PAT growth in 3-5 years → FY26 PAT ₹222 Cr up 177% (= PARTIAL)
Missed
- Guided 1-2 months for insurance/Ayushman implementation → not fully operational (= MISS)
Earnings Call Transcript filed with BSE, NSE: JSLL. Summary written with AI assistance from the document.
Jeena Sikho Lifecare Ltd: key numbers
- Share price
- ₹367.95
- Market cap
- ₹4,575 Cr
- Revenue (annual)
- ₹801.4 Cr
- Net profit (annual)
- ₹221.8 Cr
- P/E (TTM)
- 19.3×Sector 43.8×
- Promoter holding
- 63.67%+0.05% QoQ
- FII holding
- 4.49%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Jeena Sikho Lifecare Ltd
All →Jeena Sikho Lifecare Product Launch
Jeena Sikho Lifecare launched ten new Ayurvedic healthcare products in the domestic market on November 11, 2026. The filing gives product-wise details under SEBI product-launch disclosure rules.
Jeena Sikho Lifecare Merger & Restructuring Worth ₹0.03 Cr
Jeena Sikho Lifecare's board approved incorporating Ayugenomics Private Limited as a subsidiary, holding 60%. The company will invest Rs 3 lakh, subject to statutory approvals.
- Value
- ₹0.03 Cr
Jeena Sikho Lifecare Board Meeting Date
Jeena Sikho Lifecare has scheduled a board meeting for 14 Nov 2026 to consider unaudited Q1 FY27 financial results. The trading window is closed from 1 Oct to 16 Nov 2026.
Jeena Sikho Lifecare Other Announcement
Jeena Sikho Lifecare Ltd filed its quarterly shareholding pattern for the quarter ended September 30, 2026, as per regulatory requirements.
Jeena Sikho Lifecare Employee Stock Options
Jeena Sikho Lifecare allotted 23,374 equity shares under its ESOS 2024 scheme. This allotment increases the company's total paid-up equity share capital.
Jeena Sikho Lifecare Product Launch
Jeena Sikho Lifecare Limited has launched eight new Ayurvedic healthcare, wellness, and nutraceutical products. These new offerings are now available in the domestic market.